Amicus Therapeutics Announces U.S. Regulatory Pathway for Migalastat for Fabry Disease

CRANBURY, N.J., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, announces its planned regulatory pathway to collect additional data to support full...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news